Severe, long-standing DME with cystoid changes, subretinal detachment, and high inflammatory cytokine burden tends to respond better to dual ANG2/VEGF-A inhibition than VEGF monotherapy. Faricimab ...
When initiating therapy, Abbey describes a cautious approach, typically treating the worse-seeing eye first rather than performing bilateral injections at the initial visit. After observing the ...
Desk workers reported 99.2 hours of weekly screen time, with weekday exposure comprising 93% of waking hours, underscoring ...
The trials are evaluating DURAVYU (vorolanib intravitreal insert) for the treatment of diabetic macular edema (DME).
A team of University of Michigan investigators reported that their multimodal, chronic disease self-management support program for people living with glaucoma, SEE, was linked to an approximate 20% ...
Pitha and colleagues observed a general correlation between patterns of ophthalmic medication and total drug shortage reports in the US. Though ophthalmic drug shortages accounted for 15% of all ...
The 6-month Support, Educate, Empower (SEE) program was associated with a 20% improvement in glaucoma treatment adherence and reduced distress among adult patients. University of Utah data show US ...
In this podcast, Philadelphia cornea and glaucoma surgeon Brian Shafer, MD, discusses the procedures and processes involved ...
Stargardt programs address ABCA4 payload constraints via dual-AAV platforms (VG801, AAVB-039) and explore first ...
Ocugen has completed enrollment in liMeliGhT, its phase 3 clinical trial of OCU400 for the treatment of retinitis pigmentosa (RP). The company describes liMeliGhT as a 1-year clinical trial that will ...
The conversation explored DME subtypes, treatment selection, and the roles of VEGF, ANG2, and inflammatory cytokines—particularly in severe or poorly controlled patients who respond inadequately to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results